SAB Biotherapeutics (SABS) Change in Acquisitions & Divestments (2024 - 2026)

SAB Biotherapeutics has reported Change in Acquisitions & Divestments for 3 years, with the latest figure at $74.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 1473.26% year-over-year to $74.6 million; the trailing twelve-month figure through Mar 2026 stood at $91.1 million (changed N/A YoY), and the FY2025 full-year result was $21.3 million, down 17.66% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $74.6 million, up from $11.3 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $74.6 million in Q1 2026, with the low at $3.8 million in Q3 2024.
• Historically, Change in Acquisitions & Divestments has averaged $18.4 million across 3 years, with a median of $8.0 million in 2024.
• Annual changes were most pronounced in 2025 — Change in Acquisitions & Divestments advanced 5.38% — and 2026, when it soared 1473.26%.
• SAB Biotherapeutics' Change in Acquisitions & Divestments stood at $10.7 million in 2024, then gained by 5.38% to $11.3 million in 2025, then soared by 561.86% to $74.6 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $74.6 million (Q1 2026), $11.3 million (Q4 2025), and $5.2 million (Q2 2025), per Business Quant data.